Melbourne-ba sed Orpharma
has announced approval by
New Zealand’s MEDSAFE
regulator for Pheburane, an
improved formulation of sodium
phenylbutyrate which is indicated
as an adjunctive therapy in the
chronic management of rare urea
cycle disorders (UCDs).
It’s estimated that the current
patient population in NZ with UCDs
is less than ten.
Pheburane was also recently
granted marketing authorisation
in Canada, South Korea and Israel,
with Orpharma currently working
on obtaining Therapeutic Goods
Administration approval.
Its the only “taste-masked” coated
formulation of phenylbutyrate,
which in its normal form is well
known for extremely bitter taste
which may compromise treatment
adherence, particularly in children.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Oct 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.